EA201692091A1 - Хиноксалиновые соединения и их применение - Google Patents

Хиноксалиновые соединения и их применение

Info

Publication number
EA201692091A1
EA201692091A1 EA201692091A EA201692091A EA201692091A1 EA 201692091 A1 EA201692091 A1 EA 201692091A1 EA 201692091 A EA201692091 A EA 201692091A EA 201692091 A EA201692091 A EA 201692091A EA 201692091 A1 EA201692091 A1 EA 201692091A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
chinoxaline
application
derivatives
nampt
Prior art date
Application number
EA201692091A
Other languages
English (en)
Russian (ru)
Inventor
Кеннет М. Гигстад
Дэвид П. Кардин
Такахару Хираяма
Масааки Хиросе
Юнбо Ху
Хироюки Какеи
Хонг Миунг Ли
Такаси Мотоядзи
Нориюки Нии
Чжань Ши
Степан Вискоцил
Хироюки Ватанабе
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201692091A1 publication Critical patent/EA201692091A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201692091A 2014-04-18 2015-04-17 Хиноксалиновые соединения и их применение EA201692091A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981273P 2014-04-18 2014-04-18
JOP20150074 2015-04-16
PCT/US2015/026275 WO2015161142A1 (en) 2014-04-18 2015-04-17 Quinoxaline compounds and uses thereof

Publications (1)

Publication Number Publication Date
EA201692091A1 true EA201692091A1 (ru) 2017-04-28

Family

ID=54324592

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692091A EA201692091A1 (ru) 2014-04-18 2015-04-17 Хиноксалиновые соединения и их применение

Country Status (9)

Country Link
US (1) US10144742B2 (cg-RX-API-DMAC7.html)
EP (1) EP3131881A4 (cg-RX-API-DMAC7.html)
JP (1) JP6510556B2 (cg-RX-API-DMAC7.html)
CN (1) CN106458934B (cg-RX-API-DMAC7.html)
BR (1) BR112016024298A2 (cg-RX-API-DMAC7.html)
CA (1) CA2946130A1 (cg-RX-API-DMAC7.html)
EA (1) EA201692091A1 (cg-RX-API-DMAC7.html)
TW (1) TW201625578A (cg-RX-API-DMAC7.html)
WO (1) WO2015161142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
BR112019006778A2 (pt) 2016-10-18 2019-10-15 Seattle Genetics Inc Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN106883188B (zh) * 2017-01-19 2020-06-30 上海交通大学 一种5-氢-1, 4-苯并二氮杂卓类化合物及其合成方法
US11718589B2 (en) * 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
CA3059255A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
MA51189A (fr) 2017-04-27 2020-03-04 Seattle Genetics Inc Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
US20210137960A1 (en) * 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
WO2020086547A1 (en) * 2018-10-22 2020-04-30 Yale University IDENTIFICATION OF PPM1D MUTATIONS AS A NOVEL BIOMARKER FOR NAMPTi SENSITIVITY
CN113507931B (zh) 2018-11-21 2025-05-27 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
US20230041576A1 (en) * 2019-11-21 2023-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY
US20230310424A1 (en) * 2020-11-20 2023-10-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing nicotinamide phosphoribosyl transferase activity
US20230321086A1 (en) * 2020-11-20 2023-10-12 Universiy of Pittsburgh - of the Commonwealth System of Higher Education Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity
CA3202961A1 (en) * 2020-12-18 2022-06-23 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN114573517B (zh) * 2022-03-10 2024-04-26 新乡医学院 一种喹喔啉类化合物及其制备方法与应用
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024036288A2 (en) * 2022-08-11 2024-02-15 Maplight Therapeutics, Inc. Gpr6 inverse agonists
AU2024267728A1 (en) * 2023-05-09 2025-11-06 Amgen Inc. 6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators
WO2025117536A1 (en) * 2023-11-29 2025-06-05 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Hormone receptor modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
AR043059A1 (es) * 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
US7189724B2 (en) * 2003-04-15 2007-03-13 Valeant Research And Development Quinoxaline derivatives having antiviral activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
JP2007099641A (ja) 2005-09-30 2007-04-19 Tsumura & Co インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物
CN1966500B (zh) * 2005-11-17 2011-03-30 中国科学院上海药物研究所 一类喹喔啉类衍生物、制法及用途
US8119656B2 (en) * 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010023307A1 (en) 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
CN101514192B (zh) * 2009-04-02 2012-05-23 山东大学 具有逆转肿瘤细胞多药耐药活性的喹喔啉酮类衍生物及其制备方法
WO2010142735A1 (en) 2009-06-09 2010-12-16 Topotarget A/S Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
HUE024874T2 (en) 2009-09-03 2016-02-29 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP2013522171A (ja) 2010-03-01 2013-06-13 ミレクシス， インコーポレイテッド 化合物およびその治療用途
US20130317027A1 (en) 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
EP2552444B1 (en) 2010-04-01 2018-10-10 Council of Scientific & Industrial Research NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
RU2016116533A (ru) 2010-09-03 2018-11-30 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
PH12013500412A1 (en) 2010-09-03 2013-04-22 Forma Tm Llc Novel compounds and compositions for the inhibition of nampt
TW201216963A (en) 2010-09-03 2012-05-01 Forma Therapeutics Inc Novel compounds and compositions for the inhibition of NAMPT
MX2013005479A (es) 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
US9469615B2 (en) * 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
US9073902B2 (en) 2011-01-05 2015-07-07 Bioenergenix, Llc Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK
EP2681207B1 (en) 2011-03-02 2016-12-28 Bioenergenix Heterocyclic compounds for the inhibition of pask
US20120225846A1 (en) 2011-03-02 2012-09-06 Bioenergenix Heterocyclic compounds for the inhibition of pask
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
RU2617643C2 (ru) 2011-05-09 2017-04-25 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
JP2014518223A (ja) 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
US20160031813A1 (en) 2011-11-11 2016-02-04 Michael L. Curtin Nampt Inhibitors
WO2013082150A1 (en) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt)
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
DE102012004054A1 (de) 2012-03-02 2013-09-05 Volkswagen Ag Rollfalzkopf, Anlage und Verfahren zum Rollfalzen mit einem Tandemrollensatz
EP2820017B1 (en) 2012-03-02 2016-12-21 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
MX2014013734A (es) 2012-05-11 2015-06-10 Abbvie Inc Inhibidores de nampt.
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
US9334264B2 (en) 2012-05-11 2016-05-10 Abbvie Inc. NAMPT inhibitors
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013170115A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
RU2015102278A (ru) 2012-06-27 2016-08-20 САНФЛАУЭР РИСЕРЧ ЭлЭлСи Соединения и их терапевтическое применение
GEP20186871B (en) 2013-12-24 2018-06-25 Inc Oncotartis Benzamide and nicotinamide compounds and methods of using same

Also Published As

Publication number Publication date
CN106458934B (zh) 2019-08-16
JP2017514809A (ja) 2017-06-08
TW201625578A (zh) 2016-07-16
CN106458934A (zh) 2017-02-22
BR112016024298A2 (pt) 2018-07-10
CA2946130A1 (en) 2015-10-22
WO2015161142A1 (en) 2015-10-22
JP6510556B2 (ja) 2019-05-08
EP3131881A1 (en) 2017-02-22
EP3131881A4 (en) 2017-09-06
US20170174704A1 (en) 2017-06-22
US10144742B2 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691421A1 (ru) Гетероарилы и их применение
EA201591509A1 (ru) Ингибиторы cdc7
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
JO3668B1 (ar) مركبات بلاديينوليد البيريدين وطرق استعمالها
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4